Treatment for glioblastoma (GBM)
This site is intended for US healthcare professionals only.

Preventing and managing dermatologic adverse events (dAEs)

nCompass™ brochure

Your guide to preventing, identifying, and managing dAEs for patients using Optune to help maximize time on therapy

View this PDF

References: 1. Lacouture ME, Davis ME, Elzinga G, et al. Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma. Semin Oncol. 2014;41(3 suppl 4):S1-14. 2. Novocure Data on File OPT-147.
3. Jennings DL II, Sumrall AL, Haggstrom DE. Classification of dermatologic adverse events and management strategies in patients receiving therapy with Optune for high grade gliomas. Poster presented at: 2016 Society for NeuroOncology (SNO) Annual Meeting: November 17-20, 2016; Scottsdale, AZ.

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).